Total Payments
$1.1M
2024 Payments
$222,307
Companies
33
Transactions
2,267
Medicare Patients
2,174
Medicare Billing
$447,219
Payment Breakdown by Category
Other$918,754 (80.5%)
Travel$92,333 (8.1%)
Consulting$69,982 (6.1%)
Food & Beverage$30,130 (2.6%)
Research$29,416 (2.6%)
Education$371.15 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $918,754 | 418 | 80.5% |
| Travel and Lodging | $92,333 | 646 | 8.1% |
| Consulting Fee | $69,982 | 22 | 6.1% |
| Food and Beverage | $30,130 | 1,113 | 2.6% |
| Unspecified | $29,416 | 55 | 2.6% |
| Education | $371.15 | 13 | 0.0% |
Payments by Type
General
$1.1M
2,212 transactions
Research
$29,416
55 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $330,009 | 667 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $283,934 | 447 | $0 (2024) |
| Allergan, Inc. | $247,346 | 491 | $0 (2021) |
| ITI, Inc. | $77,301 | 93 | $0 (2023) |
| Vanda Pharmaceuticals Inc. | $48,404 | 85 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46,876 | 58 | $0 (2024) |
| Axsome Therapeutics, Inc. | $45,770 | 40 | $0 (2024) |
| EISAI INC. | $15,256 | 44 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $13,220 | 53 | $0 (2022) |
| IDORSIA PHARMACEUTICALS US INC | $11,812 | 18 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $222,307 | 390 | ABBVIE INC. ($52,704) |
| 2023 | $234,166 | 366 | ABBVIE INC. ($130,529) |
| 2022 | $169,507 | 292 | ABBVIE INC. ($56,656) |
| 2021 | $123,577 | 301 | AbbVie Inc. ($90,120) |
| 2020 | $77,755 | 157 | Teva Pharmaceuticals USA, Inc. ($40,805) |
| 2019 | $122,146 | 267 | Allergan Inc. ($73,644) |
| 2018 | $134,521 | 335 | Allergan Inc. ($95,455) |
| 2017 | $57,006 | 159 | Allergan Inc. ($44,273) |
All Payment Transactions
2,267 individual payment records from CMS Open Payments — Page 1 of 91
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $496.95 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $233.16 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $165.15 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $59.59 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.73 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $1,453.90 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | — | Cash or cash equivalent | $446.00 | Research |
| Study: TV50717-CNS-40223 • Category: Central Nervous System | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | — | Cash or cash equivalent | $446.00 | Research |
| Study: TV50717-CNS-40223 • Category: Central Nervous System | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | — | Cash or cash equivalent | $446.00 | Research |
| Study: TV50717-CNS-40223 • Category: Central Nervous System | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | — | Cash or cash equivalent | $446.00 | Research |
| Study: TV50717-CNS-40223 • Category: Central Nervous System | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | — | Cash or cash equivalent | $257.00 | Research |
| Study: TV50717-CNS-40223 • Category: Central Nervous System | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $250.48 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $169.29 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $101.77 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $46.44 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Neuropsychiatry | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 11/26/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/26/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $3.92 | General |
| Category: SCHIZOPHRENIA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TV50717-CNS-40223 | Teva Pharmaceuticals USA, Inc. | $29,416 | 55 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 386 | 1,896 | $259,125 | $118,316 |
| 2022 | 4 | 477 | 1,728 | $226,845 | $116,996 |
| 2021 | 5 | 574 | 1,902 | $234,850 | $108,674 |
| 2020 | 6 | 737 | 2,180 | $263,255 | $103,233 |
Total Patients
2,174
Total Services
7,706
Medicare Billing
$447,219
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 177 | 923 | $138,450 | $71,182 | 51.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 182 | 946 | $113,520 | $43,053 | 37.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $7,155 | $4,081 | 57.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 174 | 791 | $118,650 | $68,989 | 58.1% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 180 | 814 | $97,680 | $41,542 | 42.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 31 | 31 | $8,215 | $4,857 | 59.1% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 92 | 92 | $2,300 | $1,608 | 69.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 190 | 813 | $121,950 | $63,410 | 52.0% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 192 | 815 | $97,800 | $38,631 | 39.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 25 | 25 | $6,625 | $3,074 | 46.4% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 154 | 234 | $5,850 | $2,521 | 43.1% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 13 | 15 | $2,625 | $1,039 | 39.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 211 | 884 | $132,600 | $52,098 | 39.3% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 215 | 902 | $108,240 | $42,854 | 39.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 40 | 40 | $10,600 | $4,569 | 43.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 36 | 39 | $5,070 | $1,508 | 29.8% |
| G0444 | Annual depression screening, 15 minutes | Office | 2020 | 86 | 89 | $2,225 | $1,396 | 62.8% |
| 96127 | Brief emotional or behavioral assessment | Office | 2020 | 149 | 226 | $4,520 | $808.22 | 17.9% |
About Dr. Ann Groover, M.D
Dr. Ann Groover, M.D is a Psychiatry healthcare provider based in Calhoun, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871664995.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ann Groover, M.D has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $222,307 received in 2024. These payments were reported across 2,267 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($918,754).
As a Medicare-enrolled provider, Groover has provided services to 2,174 Medicare beneficiaries, totaling 7,706 services with total Medicare billing of $447,219. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Calhoun, GA
- Active Since 11/11/2006
- Last Updated 12/04/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1871664995
Products in Payments
- VRAYLAR (Drug) $577,141
- AUSTEDO (Drug) $230,463
- CAPLYTA (Drug) $124,177
- Austedo XR (Drug) $52,222
- FANAPT (Drug) $48,042
- Auvelity (Drug) $45,770
- Dayvigo (Drug) $15,256
- LATUDA (Drug) $13,220
- QUVIVIQ (Drug) $11,812
- Aristada 441 mg (Drug) $5,419
- SD809-TD (Drug) $829.83
- INGREZZA (Drug) $742.72
- REXULTI (Drug) $734.86
- ARISTADA (Drug) $483.96
- Qelbree (Drug) $347.49
- TRINTELLIX (Drug) $341.96
- INVEGA SUSTENNA (Drug) $228.18
- NAMZARIC (Drug) $200.00
- Fanapt (Drug) $199.88
- ABILIFY MAINTENA (Drug) $169.14
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.